Výsledky vyhledávání - "Judy Moczygemba"

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies

Autor: Lillian L, Siu, Eric K, Rowinsky, Lisa A, Hammond, Geoffrey R, Weiss, Manuel, Hidalgo, Gary M, Clark, Judy, Moczygemba, Les, Choi, Ron, Linnartz, Nicholas C, Barbet, Ivo T, Sklenar, Renaud, Capdeville, Gregory, Gan, Carl W, Porter, Daniel D, Von Hoff, S Gail, Eckhardt

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 8(7)

SAM486A is a novel inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC). This study was performed to characterize the toxicity profile and the pharmacological behavior and to determine the maximum tolerated dose (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0f76fd831dcbf99cb316f9d71157d217
https://pubmed.ncbi.nlm.nih.gov/12114416

Zobrazit plný text záznamu

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

Autor: Tom Griffin, P. Khoury, Joanne L. Blum, Eric K. Rowinsky, S. Diab, D. D. Von Hoff, Stephen E. Jones, M. A. Villalona-Calero, Richard M. Elledge, Maura Kraynak, P. Kromelis, Judy Moczygemba

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 12(5)

Summary Background Based on preclinical studies demonstrating that treatment with paclitaxel upregulates intratumoral thymidine phosphorylase (dTHdPase), which catalyzes the final step in the conversion of the oral fluoropyrimidine capecitabine to 5-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7e01ac32e0df904d7b4f7de58cc9d86
https://pubmed.ncbi.nlm.nih.gov/11432617

Zobrazit plný text záznamu

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies

Autor: Judy Moczygemba, Ronald Drengler, Daniel D. Von Hoff, John R. MacDonald, Miguel A. Villalona-Calero, Manuel Hidalgo, Lillian L. Siu, Sharyn D. Baker, Carolyn D. Britten, Lisa A. Hammond, John G. Kuhn, Sally Felton, Charlotte Smith, S. Gail Eckhardt, S. Smith, Eric K. Rowinsky, Steve Weitman, Gary M. Clark

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(24)

PURPOSE: To evaluate the toxicity and pharmacologic behavior of the novel mushroom-derived cytotoxin irofulven administered as a 5-minute intravenous (IV) infusion daily for 5 days every 4 weeks to patients with advanced solid malignancies. PATIENTS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a6f8ef2a23b723eb70a2259849ad7d
https://pubmed.ncbi.nlm.nih.gov/11118470

Zobrazit plný text záznamu

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

Autor: Eric K. Rowinsky, Lon Smith, Ronald Drengler, Alison L. Hannah, Allison Thurman, Kevin R. Sweeney, John R. Eckardt, Maura Kraynak, Sharyn D. Baker, Gillian F. Cropp, S. Gail Eckhardt, Judy Moczygemba, Jinee Rizzo, Lisa A. Hammond, Daniel D. Von Hoff, Miguel A. Villalona-Calero, Geoffrey R. Weiss, John G. Kuhn

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(4)

PURPOSE: To evaluate the clinical feasibility and pharmacologic behavior of the platelet-derived growth factor (PDGF) tyrosine kinase inhibitor SU101, administered on a prolonged, intermittent dosing schedule to patients with advanced solid malignanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f279ddf4c424582d1b6e74b2e3bd6242
https://pubmed.ncbi.nlm.nih.gov/10561165

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání